With US poultry producers facing persistent challenges from subclinical necrotic enteritis, BiomEdit, a pioneering biotech firm, is introducing an approach that it believes could transform animal health and productivity. In a wide-ranging interview at the Animal AgTech Innovation Summit in Dallas in April, Aaron Schacht, CEO of BiomEdit, revealed promising new developments in how the company is tackling that disease.

As the industry continues its shift away from antibiotics, subclinical necrotic enteritis remains a costly and underdiagnosed issue — silently degrading gut health, feed efficiency, and growth rates, stressed the CEO. Schacht told the outlet current tools only suppress outbreaks without eliminating the underlying threat. BiomEdit’s solution, CPerf LLV* (BE-101), is designed to address subclinical necrotic enteritis at the root cause.

The product is a novel bioengineered product that combines two Lactobacillus reuteri (L. reuteri) strains — identified from healthy chickens — each genetically engineered to produce antibodies that neutralize key toxins produced by C. perfringens, including NetB and Alpha toxin, both of which damage intestinal lining and compromise poultry health. To develop the antibodies, BiomEdit turned to an unlikely ally: llamas.

“One of the core strategies behind CPerf LLV* (BE-101) is the use of a probiotic strain to help stabilize gut conditions, specifically targeting inflammation and maintaining gut integrity. We selected two strains of L. reuteri for this purpose. These strains were originally isolated from the guts of chickens as part of a broader strategy: we compared microbial populations in healthy versus diseased birds,” Schacht explained.

BiomEdit expects USDA conditional licensure by Q4 2026, pending completion of environmental risk assessments, public comment periods, and final safety trials. “This is a first-of-its-kind product,” said Schacht, “so there’s no reference case. But we’ve had consistent, interactive support from USDA and are moving steadily through the approval pipeline.”

With over 9 billion broilers produced annually in the US and just 20 major integrators responsible for 97% of production, BiomEdit’s path to market is highly targeted. Pre-commercial trials, expected to begin as early as Q2 2026, will allow integrators to trial the product on their commercial farms.

Building on the success of CPerf LLV* (BE-101), BiomEdit is also turning its attention to the cattle industry. “Our technology platform was built on a foundational vision: combining a deep understanding of the animal microbiome with the tools of synthetic biology to engineer microbes capable of delivering therapeutic or biologically active molecules,” Schacht said, describing how a Gates Foundation grant helped the company apply its poultry and swine microbiome learnings to the cow’s rumen.

Source: AgNavigator